Quantcast

Industry news that matters to you.  Learn more

Biodesix and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat Test in Greater China

Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test, a precision medicine diagnostic for patients with non-small cell lung cancer (NSCLC), for clinical use in Greater China, with potential expansion into other Asia-Pacific countries.

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China

WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai and serving 2.3 million patients nationwide per year, today announced the signing of a landmark agreement for advancing precision medicine in China. It brings WuXi NextCODE’s renowned genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to begin immediately to deliver benefits to thousands of rare disease patients across China.

PPD Laboratories Opens Central Lab in Shanghai, China

Pharmaceutical Product Development, LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been established in association with Shanghai Clinical Research Center (SCRC), is equipped with cutting-edge analytical equipment to provide high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development.

Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-small-cell lung cancer (NSCLC), biomarker testing is already widely employed in the China and South Korea markets, and is set to increase to European levels in the next two years.

Ventana Receives Approval from China’s FDA for First Fully Automated IHC Companion Diagnostic Identifying ALK Protein Expression in Lung Cancer Patients

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by the Chinese Food and Drug Administration (CFDA) as a companion diagnostic to aid in the identification of patients for Pfizer’s CFDA-approved oncology product XALKORI® (crizotinib). The VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody assay is designed to identify ALK-positive patients in non-small cell lung cancer (NSCLC) patients1. The approval is based on a retrospective study that included 1100 Chinese subjects across three national hospitals where the VENTANA assay demonstrated 99.23 percent concordance with Abbott’s Vysis ALK Break Apart FISH Probe Kit.